A Phase 2 interventional study of Atorvastatin 80 mg/day and Placebo atorvastatin in Arrhythmogenic Cardiomyopathy, sponsored by Centro Cardiologico Monzino. Recruiting at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Centro Cardiologico Monzino · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if Atorvastatin 80 mg is effective to avoid functional right ventricular deterioration in patients affected by Arrhythmogenic Cardiomyopathy. It will also learn about the safety of Atorvastatin 80 mg in this type of patients. The main questions it aims to answer are:
Researchers will compare Atorvastatin 80 mg to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat Arrhythmogenic Cardiomyopathy.
Participants will:
246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.
This study's planned enrollment of 102 is above the median of 60 across 162 interventional studies indexed under Sprains and Strains.
Browse Sprains and Strains studies →Centro Cardiologico Monzino is the lead sponsor of 72 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atorvastatin arm will be composed by 51 patients affected by Arrhythmogenic Cardiomyopathy.
Drug: Atorvastatin 80 mg/day
Placebo arm will be composed by 51 patients affected by Arrhythmogenic Cardiomyopathy.
Drug: Placebo atorvastatin
Drug page: AtorvastatinStudies of AtorvastatinAtorvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
Efficacy of Atorvastatin in avoiding functional right ventricular deterioration
Variation of right ventricular free wall longitudinal strain measured by echocardiography after 18 months respect to baseline (%)
Time frame: From enrollment to the end of treatment at 18 months
Safety of Atorvastatin treatment
Monitoring of adverse events and patient's well-being.
Time frame: From enrollment to 1 month after the end of treatment (19 months)
Efficacy of Atorvastatin in avoiding morphological deterioration (ventricular volumes)
Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: ventricular volumes (ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding morphological deterioration (wall thickness )
Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: wall thickness (mm)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding morphological deterioration (cardiac function )
Deterioration from baseline of other morphological parameters measured both at echocardiography and cardiac magnetic resonance: cardiac function (%)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding arrhythmic deterioration (premature ventricular contractions)
Deterioration from baseline of arrhythmia burden: premature ventricular contractions (number in the 24h)
Time frame: From enrollment to the end of treatment at 18 months
Efficacy of Atorvastatin in avoiding arrhythmic deterioration (nonsustained ventricular arrhythmias)
Deterioration from baseline of arrhythmia burden: nonsustained ventricular arrhythmias (number)
Time frame: From enrollment to the end of treatment at 18 months
Efficacy of Atorvastatin in avoiding arrhythmic deterioration (sustained ventricular arrhythmias)
Deterioration from baseline of arrhythmia burden: sustained ventricular arrhythmias (number)
Time frame: From enrollment to the end of treatment at 18 months
Efficacy of Atorvastatin in avoiding arrhythmic deterioration (ventricular fibrillation )
Deterioration from baseline of arrhythmia burden: ventricular fibrillation (number)
Time frame: From enrollment to the end of treatment at 18 months
Efficacy of Atorvastatin in avoiding arrhythmic deterioration (ICD shocks)
Deterioration from baseline of arrhythmia burden: appropriate ICD shocks (number)
Time frame: From enrollment to the end of treatment at 18 months
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (QRS)
Deterioration from baseline of electrocardiographic parameters: QRS duration (ms)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (QT)
Deterioration from baseline of electrocardiographic parameters: QT duration (ms)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (PR)
Deterioration from baseline of electrocardiographic parameters: PR duration (ms)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (amplitudes)
Deterioration from baseline of electrocardiographic parameters: amplitude of the potential (mV)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (T wave)
Deterioration from baseline of electrocardiographic parameters: ), T wave inversion (number of presences in V1-V6)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding electrocardiographic deterioration (ԑ wave)
Deterioration from baseline of electrocardiographic parameters: ԑ wave in V1-V3 (presence)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (oxLDL)
Deterioration from baseline of blood parameters: oxLDL (mU/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (MDA)
Deterioration from baseline of blood parameters: MDA (ng/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (4HNE)
Deterioration from baseline of blood parameters: 4HNE (pg/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (estradiol)
Deterioration from baseline of blood parameters: estradiol (pg/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (testosterone)
Deterioration from baseline of blood parameters: testosterone (ng/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (BIN1)
Deterioration from baseline of blood parameters: BIN1 (pg/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (GAL3)
Deterioration from baseline of blood parameters: GAL3 (ng/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (HSP70)
Deterioration from baseline of blood parameters: HSP70 (ng/mL)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (TGFb)
Deterioration from baseline of blood parameters: TGFb (pg/mL)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (ST2)
Deterioration from baseline of blood parameters: ST2 (ng/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (BNP)
Deterioration from baseline of blood parameters: BNP (pg/mL)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (NTproBNP)
Deterioration from baseline of blood parameters: NTproBNP (pg/mL)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (hs-cTnI)
Deterioration from baseline of blood parameters: hs-cTnI (ng/L)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (CRP)
Deterioration from baseline of blood parameters: CRP (mg/L)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (IL6)
Deterioration from baseline of blood parameters: IL6 (pg/ml)
Time frame: From enrollment to the end of treatment (18 months)
Efficacy of Atorvastatin in avoiding biomarkers deterioration (TNF alfa)
Deterioration from baseline of blood parameters: TNF alfa (pg/ml)
Time frame: From enrollment to the end of treatment (18 months)
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Nov 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Centro Cardiologico Monzino